Literature DB >> 11739014

Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.

J Nagamine1, R Nagata, H Seki, N Nomura-Akimaru, Y Ueki, K Kumagai, M Taiji, H Noguchi.   

Abstract

SM-130686, an oxindole derivative, is a novel orally active GH secretagogue (GHS) which is structurally distinct from previously reported GHSs such as MK-677, NN703 and hexarelin. SM-130686 stimulates GH release from cultured rat pituitary cells in a dose-dependent manner. Half-maximum stimulation was observed at a concentration of 6.3+/-3.4 nM. SM-130686-induced GH release was inhibited by a GHS antagonist, but not by a GH-releasing hormone antagonist. SM-130686 dose-dependently inhibited the binding of radiolabeled ligand, (35)S-MK-677, to human GHS receptor 1a (IC(50)=1.2 nM). This indicates that SM-130686 stimulates GH release through the GHS receptor. The effect of a single oral administration of SM-130686 on GH release in pentobarbital-anesthetized rats was studied. After treatment with 10 mg/kg SM-130686, plasma GH concentrations measured by radioimmunoassay significantly increased, reaching a peak at 20-45 min, and remained above baseline during the experimental period (60 min). The anabolic effect of repetitive SM-130686 administration was studied in rats. Rats received 10 mg/kg SM-130686 orally twice a day and were weighed every day for 9 days. At day 9 there was a significant increase in both the body weight and the fat free mass (19.5+/-2.1 and 18.1+/-7.5 g respectively). Serum IGF-I concentration was also significantly elevated 6 h after the last dose of SM-130686. An endogenous GHS ligand for the GHS receptor has recently been identified from stomach extract and designated as ghrelin. The GH-releasing activity in vitro relative to ghrelin (100%) was about 52% for SM-130686. It is likely that SM-130686 is a partial agonist for the GHS receptor. In summary, we describe here an orally active GHS, SM-130686, which acts through the GHS receptor. Repetitive administration of SM-130686 to rats, similar to repetitive administration of GH, significantly increased the fat free mass by an amount almost equal to the gain in body weight.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739014     DOI: 10.1677/joe.0.1710481

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  4 in total

1.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

2.  Synthesis of N-substituted 3-(2-aryl-2-oxoethyl)-3-hydroxyindolin-2-ones and their conversion to N-substituted (E)-3-(2-aryl-2-oxoethylidene)indolin-2-ones: synthetic sequence, spectroscopic characterization and structures of four 3-hydroxy compounds and five oxoethylidene products.

Authors:  Diana Becerra; Juan Castillo; Braulio Insuasty; Justo Cobo; Christopher Glidewell
Journal:  Acta Crystallogr C Struct Chem       Date:  2020-04-20       Impact factor: 1.172

Review 3.  Catalytic asymmetric synthesis of biologically important 3-hydroxyoxindoles: an update.

Authors:  Bin Yu; Hui Xing; De-Quan Yu; Hong-Min Liu
Journal:  Beilstein J Org Chem       Date:  2016-05-18       Impact factor: 2.883

4.  Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.

Authors:  Junghun Lee; Ahreum Kwon; Hyun Wook Chae; Woo Jung Lee; Tae Hyuk Kim; Ho Seong Kim
Journal:  Yonsei Med J       Date:  2018-12       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.